NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

GERN

Geron Corp

Jul 15 • 04:00PM ET

1.26

Dollar change -0.08
Percentage change -5.97	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD FATE EXEL ACAD ONC PTCT ALLO ETON IMMP ATNM

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT IDNA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.21	Insider Own	5.26%	Shs Outstand	636.92M	Perf Week	-9.35%
Market Cap	802.52M	Forward P/E	-	EPS next Y	-0.05	Insider Trans	0.42%	Shs Float	603.39M	Perf Month	-19.23%
Enterprise Value	651.47M	PEG	-	EPS next Q	-0.03	Inst Own	75.75%	Short Float	10.44%	Perf Quarter	-8.70%
Income	-139.02M	P/S	6.90	EPS this Y	52.95%	Inst Trans	5.23%	Short Ratio	5.82	Perf Half Y	-60.25%
Sales	116.29M	P/B	2.99	EPS next Y	59.22%	ROA	-26.62%	Short Interest	62.99M	Perf YTD	-64.41%
Book/sh	0.42	P/C	2.01	EPS next 5Y	-	ROE	-45.35%	52W High	5.06 -75.10%	Perf Year	-73.53%
Cash/sh	0.63	P/FCF	-	EPS past 3/5Y	8.65% 5.60%	ROIC	-27.84%	52W Low	1.17 7.69%	Perf 3Y	-36.04%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	280.92% 178.45%	Gross Margin	97.08%	Volatility	6.67% 6.65%	Perf 5Y	-42.47%
Dividend TTM	-	EV/Sales	5.60	EPS Y/Y TTM	39.09%	Oper. Margin	-115.48%	ATR (14)	0.09	Perf 10Y	-70.83%
Dividend Ex-Date	-	Quick Ratio	6.97	Sales Y/Y TTM	22264.23%	Profit Margin	-119.54%	RSI (14)	37.63	Recom	2.10
Dividend Gr. 3/5Y	- -	Current Ratio	7.87	EPS Q/Q	67.54%	SMA20	-12.16%	Beta	0.75	Target Price	3.39
Payout	-	Debt/Eq	0.92	Sales Q/Q	12927.30%	SMA50	-11.55%	Rel Volume	0.68	Prev Close	1.34
Employees	229	LT Debt/Eq	0.86	Earnings	May 07 BMO	SMA200	-51.67%	Avg Volume	10.82M	Price	1.26
IPO	Jul 31, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.90% -17.98%	Trades		Volume	7,380,595	Change	-5.97%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Sell	$1
May-08-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$1.50
Feb-27-25	Downgrade	B. Riley Securities	Buy → Neutral	$3.50 → $2
Feb-26-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Initiated	H.C. Wainwright	Buy	$8
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Initiated	Leerink Partners	Outperform	$7
Apr-30-24	Downgrade	Robert W. Baird	Outperform → Neutral	$4.50
Apr-29-24	Initiated	TD Cowen	Buy	$10
Mar-15-24	Reiterated	Needham	Buy	$4 → $5
Sep-12-23	Upgrade	Goldman	Neutral → Buy	$4
Mar-28-23	Initiated	Goldman	Neutral	$3
Oct-28-22	Initiated	Wedbush	Outperform	$5
Jul-28-22	Resumed	B. Riley Securities	Buy	$4
Nov-02-21	Initiated	Robert W. Baird	Outperform	$4
Feb-18-21	Resumed	B. Riley Securities	Buy	$4
Aug-03-20	Initiated	Stifel	Buy	$3
Nov-19-19	Resumed	B. Riley FBR	Buy	$4
Sep-03-19	Initiated	H.C. Wainwright	Buy	$4
Aug-15-19	Initiated	Cantor Fitzgerald	Overweight	$4

Show Previous Ratings

Today 08:58AM	Geron Presents Positive RYTELO Data for LR-MDS at ASCO & EHA, Highlights Efficacy, Myelofibrosis Program Progress (Insider Monkey) -5.97%
Jul-07-25 09:10AM	Leerink Partners Reiterates a Buy Rating on Geron Corporation (GERN) (Insider Monkey)
Jun-18-25 04:10PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.90%
May-28-25 08:30AM	Geron Announces Presentations at ASCO and EHA Underscoring RYTELO (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program (Business Wire)
May-19-25 04:15PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.45%
08:55AM	Loading…
May-13-25 08:55AM	Why Geron Corporation (GERN) Is The Best Low Priced Biotech Stock to Buy Now (Insider Monkey) -6.25%
May-08-25 03:07AM	Geron Corp (GERN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic ... (GuruFocus.com)
12:09AM	Q1 2025 Geron Corp Earnings Call (Thomson Reuters StreetEvents)
May-07-25 04:35PM	Why Geron Stock Crept Higher Today (Motley Fool)
12:51PM	Geron outlines strategies to boost RYTELO adoption and anticipates Phase III myelofibrosis trial results in 2026 (Seeking Alpha)
12:50PM	Geron Corporation (GERN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:30AM	Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:27AM	Geron: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
04:07AM	GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights (PR Newswire)
10:01AM	Loading…
Apr-30-25 10:01AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-24-25 12:27PM	Geron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights GERN (GlobeNewswire)
Apr-18-25 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
11:45AM	Is Geron Corp. (NASDAQ:GERN) the Most Promising Penny Stock According to Analysts? (Insider Monkey)
Apr-16-25 10:02AM	Is Geron Corp. (NASDAQ:GERN) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-15-25 09:34AM	GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights (PR Newswire) -5.30%
Apr-10-25 09:04AM	GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights (PR Newswire) -6.47%
Apr-08-25 10:20AM	Should You Invest in Geron Corporation (GERN)? (Insider Monkey) -9.22%
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-04-25 04:21AM	GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights (PR Newswire) -6.12%
Mar-31-25 04:32PM	Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments (Seeking Alpha) -6.92%
04:30PM	Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025 (Business Wire)
02:34PM	Biotech Stocks Q1 2025 Recap: Winners And Underperformers (Seeking Alpha)
Mar-28-25 09:30AM	GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights (PR Newswire)
Mar-25-25 05:52PM	Geron Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - GERN (PR Newswire)
05:43PM	Loading…
05:43PM	Is Geron Corporation (NASDAQ:GERN) The Top Penny Stock That Will Skyrocket? (InsiderMonkey)
Mar-21-25 01:43PM	Geron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights GERN (GlobeNewswire)
Mar-19-25 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-18-25 05:45AM	Shareholders of Geron Corporation Should Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERN (PR Newswire)
Mar-11-25 04:30PM	Geron Announces European Commission Approval of RYTELO (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS (Business Wire) +10.62%
04:02PM	Geron Corporation Announces Departure of Chief Executive Officer (Business Wire)
Feb-26-25 07:30AM	Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (Business Wire) -32.07%
Feb-21-25 09:00AM	Geron to Participate at Upcoming Investor Conferences in March 2025 (Business Wire)
Feb-19-25 04:15PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-25 09:00AM	Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 (Business Wire)
Jan-21-25 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-28-24 09:52AM	Geron Corp. (GERN) Ends Trading Week Defying Market Bloodbath (Insider Monkey)
Dec-19-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-14-24 06:40AM	Geron announces positive CHMP opinion for Rytelo (TipRanks)
Dec-13-24 06:36AM	Geron Announces Positive CHMP Opinion for RYTELO (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS (Business Wire)
Dec-10-24 09:00AM	Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis (Business Wire)
09:00AM	Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies (Business Wire)
Nov-27-24 09:00AM	Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-21-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-11-24 04:30PM	Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development (Business Wire)
09:00AM	Geron to Participate in the Stifel 2024 Healthcare Conference (Business Wire)
Nov-08-24 07:29AM	Geron Secures $250M Funding and Strong Q3 Sales (TipRanks)
Nov-07-24 07:10AM	Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million (GlobeNewswire)
07:01AM	Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors (Business Wire)
07:00AM	Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Nov-05-24 09:00AM	Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO (imetelstat) in Myeloid Hematologic Malignancies (Business Wire)
Oct-17-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-15-24 04:30PM	Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-12-24 12:26PM	Is Geron Corporation (GERN) the Best Growth Stock Under $10 to Buy? (Insider Monkey)
Oct-10-24 09:36AM	Is Geron Corporation (GERN) the Best Stock Under $10 With High Potential? (Insider Monkey)
Oct-09-24 05:27PM	Geron Corp (GERN) Q2 2024 Earnings Call Highlights: Strong Financial Position Amid Early Rytelo ... (GuruFocus.com)
08:04AM	Wall Street Analysts Rate Geron Corporation (GERN) as a Buy Amid Strong Growth Prospects (Insider Monkey)
Sep-19-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-09-24 04:15PM	Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer (Business Wire)
Aug-22-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-24 07:00AM	Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
Jul-26-24 07:30AM	Geron Announces Updated NCCN Guidelines Recommending RYTELO (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS (Business Wire) +8.62%
Jul-23-24 04:15PM	Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024 (Business Wire) -7.14%
Jul-18-24 04:30PM	Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
Jul-11-24 02:23PM	3 Under-$10 Biotech Stocks That Could Make You Rich (InvestorPlace)
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jun-20-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-24 10:00AM	3 Penny Stocks to Buy if You Want to Spend Less and Earn More (InvestorPlace)
Jun-10-24 11:58AM	Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up (Zacks) +9.80%
Jun-07-24 03:51PM	Geron stock pops on FDA approval for blood cancer drug (Yahoo Finance Video) +17.99%
03:24PM	Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers (Investopedia)
01:10PM	Stocks shrug off hot jobs report, GameStop sinks, Nvidia stock split on tap: Yahoo Finance (Yahoo Finance Video)
11:21AM	FDA Reverses Juul Ban. What Comes Next? (InvestorPlace)
11:02AM	Why Is Geron (GERN) Stock Up 18% Today? (InvestorPlace)
07:22AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-06-24 09:58PM	Geron Announces FDA Approval of RYTELO (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia (Business Wire)
May-16-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-24 10:34AM	Geron Corporation (NASDAQ:GERN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 12:55PM	GERN Stock Earnings: Geron Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:20AM	Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
06:46AM	The Top 3 Penny Stocks to Buy in April 2024 (InvestorPlace)
Apr-25-24 04:30PM	Geron to Announce First Quarter 2024 Financial Results on May 2, 2024 (Business Wire) +6.46%
Apr-18-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-03-24 04:30PM	Geron to Participate at Upcoming Investor Conferences in April (Business Wire)
Mar-19-24 09:07AM	Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Mar-15-24 03:50PM	Geron, Madrigal Pharmaceuticals jump on good news from FDA (Yahoo Finance Video) +92.00%
01:29PM	Stocks to Watch Friday: Adobe, Ulta, Fisker (The Wall Street Journal)
10:47AM	Why Is Geron (GERN) Stock Up 94% Today? (InvestorPlace)
08:57AM	Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up (Zacks)
05:00AM	Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat (FierceBiotech.com)
Mar-14-24 03:54PM	Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS (Business Wire)
Mar-13-24 10:48AM	Implied Volatility Surging for Geron (GERN) Stock Options (Zacks) -6.91%
Mar-12-24 12:28PM	Geron faces uphill battle at FDA meeting, as agency questions benefit-risk profile of imetelstat (FierceBiotech.com) -12.15%
Mar-08-24 04:20PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +7.14%

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LAWLIS V BRYAN	Director	May 09 '25	Buy	1.18	13,300	15,667	13,300	May 13 04:20 PM
Samuels Scott Alan	EVP, Chief Legal Officer	Feb 27 '25	Buy	1.61	15,000	24,150	26,682	Mar 03 06:01 AM
SCARLETT JOHN A	Chairman, President and CEO	Feb 27 '25	Buy	1.76	12,500	22,062	12,500	Mar 03 06:01 AM
Ziegler James	EVP, Chief Commercial Officer	Feb 27 '25	Buy	1.60	100,000	160,000	100,000	Mar 03 06:01 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GERN

Geron Corp

Upgrade your FINVIZ experience